{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Quince Therapeutics, Inc.
Is Quince Therapeutics, Inc. technically bullish or bearish?
As of June 13, 2025, the market trend is neutral with mixed signals, showing a shift from mildly bearish to sideways, as indicated by various technical indicators.
Who are in the management team of Quince Therapeutics, Inc.?
As of March 2022, the management team of Quince Therapeutics, Inc. includes Ms. Casey Lynch (Chairman, CEO, Co-Founder), Mr. Stephen Dominy (Co-Founder, Chief Scientific Officer), and Dr. Una Ryan (Lead Independent Director), along with several independent directors.
What does Quince Therapeutics, Inc. do?
Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for Alzheimer’s and other degenerative diseases. As of March 2025, it has a market cap of $61.84 million and reported a net profit loss of $15 million.
How big is Quince Therapeutics, Inc.?
As of Jun 18, Quince Therapeutics, Inc. has a market capitalization of 61.84 million, with net sales of 0.00 million and a net profit of -60.71 million over the last four quarters. The company reported shareholder's funds of 30.15 million and total assets of 126.15 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
